Addex Therapeutics Ltd. (ADXN) stock
ADXNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.06−0.44 (-12.57%)
Close on Nov 18, 2026Market cap $62.83KP/E –Yield –
Addex Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -CHF 2.81M. The highest annual figure on record is -CHF 1.42M in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -CHF 2.81M | – |
| FY2024 | Dec 31, 2024 | -CHF 2.76M | – |
| FY2023 | Dec 31, 2023 | -CHF 2.24M | – |
| FY2022 | Dec 31, 2022 | -CHF 10.54M | – |
| FY2021 | Dec 31, 2021 | -CHF 15.51M | – |
| FY2020 | Dec 31, 2020 | -CHF 12.24M | – |
| FY2019 | Dec 31, 2019 | -CHF 14.60M | – |
| FY2018 | Dec 31, 2018 | -CHF 1.42M | – |
| FY2017 | Dec 31, 2017 | -CHF 3.24M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -CHF 645.35K | – |
| Q2 FY2025 | Jun 30, 2025 | -CHF 732.90K | – |
| Q2 FY2024 | Jun 30, 2024 | -CHF 899.32K | – |
| Q2 FY2023 | Jun 30, 2023 | -CHF 2.55M | – |
| Q2 FY2022 | Jun 30, 2022 | -CHF 7.09M | – |
| Q2 FY2021 | Jun 30, 2021 | -CHF 4.51M | – |
See a number that looks wrong?